UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31

Benzinga · 15h ago
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $33 to $31.